Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl fumarate in adrenomyeloneuropathy
2023-506795-27-00Phase 3Authorised
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in adrenomyeloneuropathy (AMN) comparing Dimethyl fumarate with Placebo (2 arms). Primary endpoint: Change in 2 Minute Walk Test (2MWT). Planned start Jan 2024; status: authorised.
02
Drugs
dimethyl fumarate
03
Conditions
adrenomyeloneuropathy (AMN)
Beyond the preview
Go deeper on 2023-506795-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506795-27-00.